- Innocan Pharma Corporation (INNO) has been granted its first U.S. patent for its breakthrough magnesium and cannabis-based technology
- The technology, administered topically, is designed to systemically relieve pain and/or itching and is administered via spray, roll-on or lotion
- InnoCan Pharma is a pharmaceutical tech company that operates under two main segments: pharmaceuticals and consumer wellness
- InnoCan Pharma Corporation (INNO) opened trading at C$0.25 per share
Innocan Pharma Corporation (INNO) has received its first patent grant in the United States.
The United States Patent and Trademark Office (USPTO) previously issued a notice of allowance for Innocan’s patent application number 16/968,627 with claims related to the company’s combined cannabis and magnesium topical pain-relief technology.
The company’s magnesium and cannabis-based technology is designed to relieve pain and/or itching and is administered via spray, roll-on or lotion.
The company plans to file further patent applications with the USPTO, as well as with other patent offices worldwide, in order to further establish its novel cannabis-based IP portfolio.
“We are glad to see a robust and vivid indication of our pain relief technology, adding to Innocan’s intellectual property portfolio,” said Innocan Pharma’s CEO, Iris Bincovich.
“Receiving the patent approval from the USPTO will assist us in our commercialization efforts,” she added.
InnoCan Pharma is a pharmaceutical tech company that operates under two main segments: pharmaceuticals and consumer wellness.
InnoCan Pharma Corporation (INNO) opened trading at C$0.25 per share.
